PAIN.V Vector Science and Therapeutics Corp.
- Market cap
- CAD 336M
- P/E
- -
- P/B
- 117.53x
- ROE
- -255.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is PAIN.V undervalued?
Graham numberThe Graham number of Vector Science and Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vector Science and Therapeutics Corp. fundamental analysis
No fundamental analysis for Vector Science and Therapeutics Corp. yet.
Vector Science and Therapeutics Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vector Science and Therapeutics Corp.
Vector Science and Therapeutics Corp. develops precision biomechanical devices and active transdermal delivery systems for musculoskeletal regeneration. The company offers cGMP-manufactured Rx peptides for physicians and patients across sports, regenerative, and longevity medicine channels. It also provides VectorMist, a commercial precision therapeutic platform, as well as Valor, a delivery system and transdermal platform. The company is based in Mequon, Wisconsin.
Full company profileVector Science and Therapeutics Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vector Science and Therapeutics Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2025 | 2026 Anlz |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -824K | -3.40M |
| EBITDA | -824K | -4.97M |
| Net Income | -898K | -5.10M |
| EPS | -0.01 | -0.03 |
| Balance Sheet | ||
| Total Assets | 3.01M | 2.49M |
| Total Liabilities | 1.28M | 491K |
| Shareholders' Equity | 1.72M | 2.00M |
| Cash & Short-term Investments | 2.72M | 1.09M |
| Cash Flow | ||
| Operating Cash Flow | -774K | -3.72M |
| Capital Expenditure | 23.5K | 212K |
| Free Cash Flow | -797K | -3.94M |
| Ratios | ||
| ROE | -52.1% | -255.0% |
| ROA | -29.9% | -204.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Vector Science and Therapeutics Corp. dividends
Vector Science and Therapeutics Corp. has not paid dividends in the last 1 fiscal years.
Who owns Vector Science and Therapeutics Corp.
- Insiders 24.29%
- Institutions 0.00%
- Public & others 75.71%
- Shares outstanding 156M
- Free float 134M
Vector Science and Therapeutics Corp. company profile
- Company name
- Vector Science and Therapeutics Corp.
- Ticker
- PAIN.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- August
- Address
- 12250 Corporate Parkway, Mequon, WI, United States, 53092
- Phone
- (833) 832-8724
- Website
- vectorscience.co
About Vector Science and Therapeutics Corp.
Vector Science and Therapeutics Corp. develops precision biomechanical devices and active transdermal delivery systems for musculoskeletal regeneration. The company offers cGMP-manufactured Rx peptides for physicians and patients across sports, regenerative, and longevity medicine channels. It also provides VectorMist, a commercial precision therapeutic platform, as well as Valor, a delivery system and transdermal platform. The company is based in Mequon, Wisconsin.
Vector Science and Therapeutics Corp. management
9- Mr. William JacksonCEO & Director · born 1960
- Mr. James Russell Starr M.A., M.B.A., MAPresident · born 1968
- Mr. Barry HixCo-Founder, Chief Commercial Officer & Director
- Stephen Gledhill CPACFO & Corporate Secretary
- Mr. Thomas BachinskiChief Technology Officer · born 1961
- Mr. Angus Jackson J.D., L.L.M., M.B.A.Managing Director of Corporate Development
- Dr. W. Bradley WorthingtonChief Medical Officer
- Mr. Darryl Drake Jr.President of Valor & Chairman of the Athletic Board
- Mr. William Dexter FowlerChief Athletic Officer for Valor · born 1986